PARAGLIDE-HF Offers Further Insight into Sacubitril/Valsartan in Heart Failure with Elevated EF

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

Related Keywords

Carlj Lavie ,Hectoro Ventura ,Mandeepr Mehra ,Sacubitril Valsartan ,European Society Of Cardiology ,Duke University Medical Center Robert Mentz ,Heart Failure Association ,Journal Of The American College Cardiology ,Duke University Medical Center ,Robert Mentz ,European Society ,Failure Association ,American College ,